"The U.S. Food and Drug Administration announced today that injectable drugs used in total parenteral nutrition (TPN) in critical shortage will be imported into the United States and available to patients this week.
TPN is an intravenous"...
(Generic versions may still be available.)
A few hypersensitivity reactions to Furoxone (furazolidone) have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. These reactions subsided following withdrawal of the drug. Nausea, emesis, headache, or malaise occur occasionally and may be minimized or eliminated by reduction in dosage or withdrawal of the drug.
Rarely, individuals receiving Furoxone (furazolidone) have exhibited an Antabuse® (disulfiram)-like reaction to alcohol characterized by flushing, slight temperature elevation, dyspnea, and in some instances, a sense of constriction within the chest. All symptomatology disappeared within 24 hours with no lasting ill effects. During nine years of clinical use and approximately 3.5 million courses of therapy (in the U. S. A. alone) in the published literature and documented case reports 43 cases have been reported † of which 14 were produced under experimental conditions with planned doses of the compound in excess of those recommended.
Three of these experienced a fall in blood pressure necessitating active therapy. Indications are that levarterenol (Levophed®) may be used to combat such hypotensive episodes since human studies show that this drug is not potentiated in patients treated with Furoxone (furazolidone) . (Indirectly acting pressor agents should be avoided.) The ingestion of alcohol in any form should be avoided during Furoxone (furazolidone) therapy and for four days thereafter to prevent this reaction.
Furoxone (furazolidone) may cause mild reversible intravascular hemolysis in certain ethnic groups of Mediterranean and Near-Eastern origin, and Negroes. This is due to an intrinsic defect of red blood cell metabolism in a small percentage of these ethnic groups, making them unusually susceptible to hemolysis by numerous compounds. It is necessary to observe such patients closely while receiving Furoxone (furazolidone) and to discontinue its use it there is any indication of hemolysis. Should not be administered to infants under 1 month of age because of the possibility of producing a hemolytic anemia due to immature enzyme systems (glutathione instability) in the early neonatal period.
Read the Furoxone (furazolidone) Side Effects Center for a complete guide to possible side effects
Last reviewed on RxList: 12/8/2004
Additional Furoxone Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.